<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249687</url>
  </required_header>
  <id_info>
    <org_study_id>43QM1901</org_study_id>
    <nct_id>NCT04249687</nct_id>
  </id_info>
  <brief_title>Treatment of Moderate to Severe Lateral Canthal Lines</brief_title>
  <acronym>READY-2</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy and safety of a single dose of
      QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with a â‰¥ 2-grade improvement from baseline on the Lateral Canthal Line Investigator and subject assessments at maximum smile at one month.</measure>
    <time_frame>Month 1</time_frame>
    <description>The investigator and subject evaluate the subject's LCL severity using a 4-grade scale (0 = none and 3 = severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who achieve grade 0 or 1 in Lateral Canthal Line Investigator scale at maximum smile.</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of subjects who experienced an adverse event</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with abnormal post-baseline QTcF and QTcB intervals</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with binding neutralizing antibodies</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lateral Canthal Lines</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QM1114-DP, a Botulinum Toxin Type A (BoNT-A); Mode of administration: intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A buffered solution; Mode of administration: intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin</intervention_name>
    <description>neuromodulator</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>QM1114-DP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 18 years of age or older.

          2. Moderate to severe LCL at maximum smile as assessed by the Investigator.

          3. Moderate to severe LCL at maximum smile as assessed by the subject.

        Exclusion Criteria:

          1. Previous use of any Botulinum toxin treatment in facial areas within 9 months prior to
             study treatment.

          2. Female who is pregnant, breast feeding, or intends to conceive a child during the
             study.

          3. Known allergy or hypersensitivity to any component of the investigational product
             (QM1114-DP) or any botulinum toxin serotype.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Galderma Aesthetics</last_name>
    <phone>8179615655</phone>
    <email>aestheticclinicaltrials@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ablon Skin Institute and Research Center</name>
      <address>
        <city>Manhattan Beach</city>
        <state>California</state>
        <zip>90266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>310-727-3376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatology Cosmetic Laser Medical Associates</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>858-657-1004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Art of Skin, MD</name>
      <address>
        <city>Solana Beach</city>
        <state>California</state>
        <zip>92075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>858-792-7546</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siperstein Dermatology Group, PLLC</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>561-364-7774</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Facial Plastic Surgicenter, Ltd</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>410-486-3400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center for Dermatology, Cosmetic &amp; Laser Surgery</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>914-241-3003</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rochester Dermatologic Surgery, Ltd</name>
      <address>
        <city>Victor</city>
        <state>New York</state>
        <zip>14564</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>585-222-1412</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aesthetic Solutions, PA</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>919-578-8623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Shannon Humphrey, Inc</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>610-714-0222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Dermaesthetics, Inc</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H-4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>604-682-7577</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

